GW Pharmaceuticals plc closed its public offering on the Nasdaq Global Market of 2.4 million American depositary shares at $115 apiece.
The underwriters fully exercised their option to buy an additional 360,000 ADSs at the offering price.
Gross proceeds from the offering totaled about $317.4 million.
Goldman Sachs & Co. LLC, Morgan Stanley, Bank of America Merrill Lynch and Cowen acted as joint book-running managers for the offering.
